Tom Cantor
Tom Cantor has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
B Sci
1 shared publicationEkambaram Ilamathi
Suffolk Nephrology Consultants, Stony Brook, NY
1 shared publicationNicolae Caraiani
Suffolk Nephrology Consultants, Stony Brook, NY
1 shared publicationZan Yang
Scantibodies Laboratory, Inc., Santee, CA
1 shared publication
Latest Publications
- 1 September 2009
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 55 (9) , 1740
Commentary
- 1 September 2009
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 55 (9) , 1740
Commentary
- 1 August 2009
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 72 (8) , 97-104
Lack of evidence for administering vitamin D analogs to kidney failure patients to improve survivability
- 1 August 2009
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 72 (8) , 97-104
Lack of evidence for administering vitamin D analogs to kidney failure patients to improve survivability
- 17 July 2007
- Published by Wiley in Seminars in Dialysis
- Vol. 20 (4) , 370-371
Correspondence: iPTH Treatment Guidelines for Caucasian versus African-American Hemodialysis Patients
- 17 July 2007
- Published by Wiley in Seminars in Dialysis
- Vol. 20 (4) , 370-371
Correspondence: iPTH Treatment Guidelines for Caucasian versus African-American Hemodialysis Patients
- 1 September 2006
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (9) , 1771-1776
Lack of Comparability of Intact Parathyroid Hormone Measurements among Commercial Assays for End-Stage Renal Disease Patients: Implication for Treatment Decisions
Background: Variability among assays used to measure intact parathyroid hormone (iPTH) is of particular concern because of the routine use of iPTH assay results to guide management of osteodystrophy and calcium metabolism in patients with end-stage renal disease (ESRD). The aim of this study was to determine the extent to which results from commercially available iPTH assays diverge from results obtained with the Nichols Allegro® Intact PTH immunoradiometric assay (IRMA), which was used as evidence in the development of the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines.
- 1 September 2006
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (9) , 1771-1776
Lack of Comparability of Intact Parathyroid Hormone Measurements among Commercial Assays for End-Stage Renal Disease Patients: Implication for Treatment Decisions
Background: Variability among assays used to measure intact parathyroid hormone (iPTH) is of particular concern because of the routine use of iPTH assay results to guide management of osteodystrophy and calcium metabolism in patients with end-stage renal disease (ESRD). The aim of this study was to determine the extent to which results from commercially available iPTH assays diverge from results obtained with the Nichols Allegro® Intact PTH immunoradiometric assay (IRMA), which was used as evidence in the development of the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines.
- 28 September 2005
- Published by Wiley in Seminars in Dialysis
- Vol. 18 (5) , 359-364
Editorials: Parathyroid Hormone Assay Drift: An Unappreciated Problem in Dialysis Patient Management
The Kidney Disease Outcomes Quality Initiative (K/DOQI) bone metabolism guidelines assume that clinicians use the Nichols intact parathyroid hormone immunoradiometric assay (iPTH IRMA) upon which K/DOQI was based. But for more than a decade, virtually all PTH assay results used for routine end-stage renal disease (ESRD) clinical management have not been generated with this test. Results from the most widely used PTH assays for ESRD patient testing in the United States have varied from 1999 to 2005. The Nichols chemiluminescent Advantage iPTH assay results shifted upwards significantly in 1999 and remained elevated until 2005. From 2003 to 2005, results from the Nichols Advantage Bio-Intact PTH assay shifted upward on average by 29% to 52%. These changes in the most widely used PTH assays have made use of the K/DOQI guidelines with these assays both inappropriate and potentially harmful to patients.
- 28 September 2005
- Published by Wiley in Seminars in Dialysis
- Vol. 18 (5) , 359-364
Editorials: Parathyroid Hormone Assay Drift: An Unappreciated Problem in Dialysis Patient Management
The Kidney Disease Outcomes Quality Initiative (K/DOQI) bone metabolism guidelines assume that clinicians use the Nichols intact parathyroid hormone immunoradiometric assay (iPTH IRMA) upon which K/DOQI was based. But for more than a decade, virtually all PTH assay results used for routine end-stage renal disease (ESRD) clinical management have not been generated with this test. Results from the most widely used PTH assays for ESRD patient testing in the United States have varied from 1999 to 2005. The Nichols chemiluminescent Advantage iPTH assay results shifted upwards significantly in 1999 and remained elevated until 2005. From 2003 to 2005, results from the Nichols Advantage Bio-Intact PTH assay shifted upward on average by 29% to 52%. These changes in the most widely used PTH assays have made use of the K/DOQI guidelines with these assays both inappropriate and potentially harmful to patients.
- 12 October 2004
- Published by Wiley in Hemodialysis International
- Vol. 8 (4) , 372-385
The opposing actions of the two parathyroid hormones, 1‐84 PTH and 7‐84 PTH: Improvement in renal bone and calcium metabolism management
Bone biopsy, while invasive, is the gold standard for assessing bone status. According to published bone biopsy studies, half of the end‐stage renal disease patients have adynamic bone disease. Compared to high‐bone‐turnover disease, adynamic bone disease has the higher mortality and is associated with arterial calcification. The treatment for high‐bone‐turnover disease is divergent from the treatment for adynamic bone disease. The parathyroid hormone (PTH) assay has been relied on as the routine, noninvasive diagnostic method to assess bone status. According to bone biopsy studies, the intact PTH assay has been demonstrated as ineffective at differentiating adynamic bone disease from normal and high‐bone‐turnover disease. For example, bone biopsy studies found the normal range for iPTH to be 451 to 1339 pg/mL and the range for adynamic bone disease to be 400 to 919 pg/mL. Intact PTH measures the sum of the two PTH hormones 1‐84 PTH and 7‐84 PTH. Specific 1‐84 PTH assays neglect the role of the 7‐84 PTH hormone, which is to lower bone turnover. According to independent bone biopsy studies, the 1‐84 PTH/7‐84 PTH ratio is 94% accurate in identifying adynamic bone disease and 94% accurate in assessing bone‐turnover status.
- 12 October 2004
- Published by Wiley in Hemodialysis International
- Vol. 8 (4) , 372-385
The opposing actions of the two parathyroid hormones, 1‐84 PTH and 7‐84 PTH: Improvement in renal bone and calcium metabolism management
Bone biopsy, while invasive, is the gold standard for assessing bone status. According to published bone biopsy studies, half of the end‐stage renal disease patients have adynamic bone disease. Compared to high‐bone‐turnover disease, adynamic bone disease has the higher mortality and is associated with arterial calcification. The treatment for high‐bone‐turnover disease is divergent from the treatment for adynamic bone disease. The parathyroid hormone (PTH) assay has been relied on as the routine, noninvasive diagnostic method to assess bone status. According to bone biopsy studies, the intact PTH assay has been demonstrated as ineffective at differentiating adynamic bone disease from normal and high‐bone‐turnover disease. For example, bone biopsy studies found the normal range for iPTH to be 451 to 1339 pg/mL and the range for adynamic bone disease to be 400 to 919 pg/mL. Intact PTH measures the sum of the two PTH hormones 1‐84 PTH and 7‐84 PTH. Specific 1‐84 PTH assays neglect the role of the 7‐84 PTH hormone, which is to lower bone turnover. According to independent bone biopsy studies, the 1‐84 PTH/7‐84 PTH ratio is 94% accurate in identifying adynamic bone disease and 94% accurate in assessing bone‐turnover status.
- 1 July 2004
- Published by Elsevier in Kidney International
- Vol. 66 (1) , 461
7-84 PTH lowers bone turnover and explains why the 1-84 PTH/7-84 PTH ratio predicts bone turnover
- 1 July 2004
- Published by Elsevier in Kidney International
- Vol. 66 (1) , 461
7-84 PTH lowers bone turnover and explains why the 1-84 PTH/7-84 PTH ratio predicts bone turnover
- 1 January 2003
- p. 69-72
The assay of the hypocalcemic PTH fragment inhibitor with PTH provides a more accurate assessment of renal osteodystrophy compared to the intact PTH assay.
As the chronic kidney disease patient is being managed for PTH, calcium, phosphate, vitamin D, calcium x phosphate product and bone quality an accurate PTH measurement is essential. Over and under PTH suppressive therapies pose significant risks of mineral metabolism disturbances, osteodystrophies and soft tissue calcifications. Until recently it was thought that there was only one hormone secreted by the parathyroid gland, 1-84 PTH (or CAP). It is now known that there is another hormone secreted by the parathyroid gland (CIP) which is most likely 7-84 PTH. 7-84 PTH has been demonstrated to be an antagonist of 1-84 PTH with inverse biological activities. 7-84 PTH has been demonstrated to be hypocalcemic and able to lower bone turnover through an inhibition of osteoclast formation resulting in an overall inhibition of bone resorption. Whereas, 1-84 PTH operates through the PTH/PTHrp receptor the 7-84 PTH appears to operate through a C terminal PTH receptor. The CAP/CIP ratio decreases in the dialysis patient when calcium increases and vice versa. The 2nd generation "intact" PTH assays measure the sum of CAP plus CIP which render them ineffective at predicting bone turnover (72% predictive) and monitoring PTH suppressive treatments. By contrast the CAP/CIP ratio predicts bone turnover in the dialysis patient with a histologically determined 93% predictability. An elevated CAP/CIP ratio indicates high bone turnover and a decreased CAP/CIP ratio indicates adynamic low bone turnover.
- 1 January 2003
- p. 69-72
The assay of the hypocalcemic PTH fragment inhibitor with PTH provides a more accurate assessment of renal osteodystrophy compared to the intact PTH assay.
As the chronic kidney disease patient is being managed for PTH, calcium, phosphate, vitamin D, calcium x phosphate product and bone quality an accurate PTH measurement is essential. Over and under PTH suppressive therapies pose significant risks of mineral metabolism disturbances, osteodystrophies and soft tissue calcifications. Until recently it was thought that there was only one hormone secreted by the parathyroid gland, 1-84 PTH (or CAP). It is now known that there is another hormone secreted by the parathyroid gland (CIP) which is most likely 7-84 PTH. 7-84 PTH has been demonstrated to be an antagonist of 1-84 PTH with inverse biological activities. 7-84 PTH has been demonstrated to be hypocalcemic and able to lower bone turnover through an inhibition of osteoclast formation resulting in an overall inhibition of bone resorption. Whereas, 1-84 PTH operates through the PTH/PTHrp receptor the 7-84 PTH appears to operate through a C terminal PTH receptor. The CAP/CIP ratio decreases in the dialysis patient when calcium increases and vice versa. The 2nd generation "intact" PTH assays measure the sum of CAP plus CIP which render them ineffective at predicting bone turnover (72% predictive) and monitoring PTH suppressive treatments. By contrast the CAP/CIP ratio predicts bone turnover in the dialysis patient with a histologically determined 93% predictability. An elevated CAP/CIP ratio indicates high bone turnover and a decreased CAP/CIP ratio indicates adynamic low bone turnover.